ANVS logo.jpg
Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
27 juin 2024 08h00 HE | Annovis Bio, Inc.
MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
ANVS logo.jpg
Annovis Bio Files Patent for New Composition of Matter for Buntanetap
26 juin 2024 08h00 HE | Annovis Bio, Inc.
MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
NodThera_logo.jpg
NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk
12 juin 2024 07h00 HE | NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk ...
Picture4
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
11 juin 2024 08h00 HE | Annovis Bio, Inc.
MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for...
ANVS logo.jpg
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
05 juin 2024 08h00 HE | Annovis Bio, Inc.
MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Alleo_Labs_Logo_Horizontal_Dark_smaller.png
Alleo Labs Announces Publication on the Use of Artificial Intelligence in Neuroscience Drug Discovery and Development
07 févr. 2024 11h30 HE | Alleo Labs
Alleo Labs, a biotechnology company based in San Francisco, publishes an article on the use of artificial intelligence in neuroscience drug discovery.
Emergen logo.png
Global Deep Brain Stimulation Market Size to Reach USD 4.27 Billion in 2032 | Emergen Research
12 déc. 2023 07h31 HE | Emergen Research
Vancouver, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The global Deep Brain Stimulation (DBS) market, valued at USD 1.70 Billion in 2022, is projected to witness a robust revenue Compound Annual Growth Rate...
logo 600X600.png
Deep Brain Stimulation Devices Market to Hit $2,508.5 Million by 2030, Rising at 9.8% CAGR | Coherent Market Insights
10 nov. 2023 08h35 HE | CMI
Burlingame, Nov. 10, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, global deep brain stimulation device market is estimated to be valued at US$ 1,188.9 million in 2022 and is...
MicrosoftTeams-image (5).png
Deep Brain Stimulation (DBS) Devices Market for Parkinson’s Disease to Reach USD 1.2 Bn by 2028 with CAGR of 5.1% - TMR Study
09 mai 2023 06h30 HE | Transparency Market Research
Wilmington, Delaware, United States, May 09, 2023 (GLOBE NEWSWIRE) -- The global deep brain stimulation devices market for Parkinson’s disease was valued at USD 0.85 Bn in 2020 and is anticipated to...
Picture1.jpg
Oncotelic Announces Formation of Animal Health Division
06 oct. 2022 08h15 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or “We”), directly and / or through its wholly owned subsidiaries...